Government-Owned Inventions; Availability for Licensing, 72742-72744 [E7-24784]
Download as PDF
<![CDATA[
72742
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
care providers and self reports. The
ultimate objective is to compare the
health care utilization of insured and
uninsured PLCO participants. The
PLCO data provides a unique
opportunity to study health care seeking
behavior after an abnormal cancer
screening test and the effect of lack of
health insurance. Individuals
randomized to the intervention arm of
the trial received screening for the PLCO
cancers. Individuals with positive
findings were referred to their doctors
for follow-up care, but no additional
care was provided by the trial. The
PLCO study then collected detailed
information on tests received for
diagnosis, clinical presentation of
disease, and cancer treatment. Since the
PLCO original data collection had not
recorded the health insurance of
participants at the time of their
screening, it is necessary to collect it
retrospectively. This feasibility study
will request information from 50
physicians and 150 participants. The
aims are to determine:
(1) The total number of physicians to
be contacted to obtain insurance
information on all PLCO participants
who had a positive cancer screening
test;
(2) The percentage of physicians
willing and able to provide insurance
information;
(3) The percentage of respondents’
patients with and without insurance,
and possibly distribution of patients by
insurance type;
(4) The number of participants for
whom the insurance status can be only
determined by self report;
(5) The percentage of PLCO
participants who are willing to respond
to the survey;
(6) The percentage of individuals who
are willing to provide information on
insurance status and type; and,
(7) The potential proportion of PLCO
participants without health insurance at
the time of screening.
The results of this feasibility study
will be used to design of a larger study
to examine the health care behavior of
insured and uninsured PLPCO
participants. This is relevant to
understand the results of the PLCO
Cancer Screening Trial and other
screening trials currently being
conducted in the U.S. The success of
these trials is conditional on
participants’ access to care following a
Number of
respondents
Type of respondents
Frequency of
response
recommendation for follow-up.
Uninsured individuals may be more
likely to join these trials than insured
ones in order to get free preventive care.
They may also be more likely to not
seek, or delay seeking, care after an
abnormal screening test even though
they are encouraged to get care and they
may be highly motivated to receive the
best care possible. It is relevant for other
decision makers to understand whether
uninsured persons are receiving
appropriate care after abnormal
screening results. The efforts to control
cancer disease and the loss of life
associated with it are concentrated on
population wide screening. These
endeavors may be compromised if a
significant proportion of the population
does not get appropriate follow-up after
screening or does not get the care
known to be effective for their disease.
Frequency of Response: One time.
Affected Public: Individuals or
households; Businesses or other forprofit. Type of Respondents: Men and
women older than 55 who participated
in the PLCO Screening trial and
physicians who provided care for them.
The annual reporting burden is shown
in the following table.
Average burden hours per response
Annual hour
burden
150
50
1
1
5 minutes (0.08) ................................
20 minutes (0.33) ..............................
12.5
16.7
Totals ....................................................................
mstockstill on PROD1PC66 with NOTICES
PLCO participants ........................................................
Physicians office staff ..................................................
200
........................
............................................................
29.2
The annualized cost to respondents is
estimated at: $488. There are no Capital
Costs to report. There are no Operating
or Maintenance Costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Dr. Maria Pisu,
Division of Preventive Medicine,
University of Alabama at Birmingham,
MT 628, 1530 3rd Avenue South,
Birmingham, AL 35294–4410, or call
non-toll-free number (205) 975–7366 or
e-mail your request, including your
address to: mpisu@uab.edu.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT:
Dated: December 11, 2007.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E7–24872 Filed 12–20–07; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
E:\FR\FM\21DEN1.SGM
21DEN1
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
mstockstill on PROD1PC66 with NOTICES
A Clinically Proven Therapeutic
Treatment and Diagnostic Tool for
Mesothelin Expressing Cancers: A
Novel Recombinant Immunotoxin SS1P
(anti-mesothelin dsFv–PE38)
Description of Technology:
Mesothelin is a cell surface
glycoprotein, whose expression is
largely restricted to mesothelial cells in
normal tissues. Mesothelin has been
shown to be highly expressed in many
cancers including malignant
mesothelioma, ovarian cancer, lung
cancer, pancreatic carcinomas, gastric
carcinomas, and other cancers.
Mesothelin has been shown to be a
target for immunotherapy and is also
being used as a tumor marker.
The technology relates to the SS1P
immunotoxin that can be used to kill
cells expressing mesothelin on their
surface, such as mesothelioma, ovarian
cancer, lung cancer, pancreatic cancer
and stomach cancer. Additionally, it can
be used for the detection of mesothelin
expressing cells present in a biological
sample.
The SSIP protein is an immunotoxin
generated by the fusion of an antimesothelin antibody Fv fragment with a
particularly high affinity (SS1), and a
∼38 kDa portion of Pseudomonas
Exotoxin A (PE38).
Applications: SS1P can be used as a
therapy for mesothelin expressing
cancers. The immunotoxin can be used
as a standalone treatment and in
combination with standard
chemotherapy.
Advantage: SS1P immunotoxin is
available for use and has been
successfully tested clinically for the
treatment of several mesothelin
expressing cancers, such as
mesothelioma and ovarian cancer with
low side effects.
Development Status: Phase 1 studies
have been completed for mesothelin
expressing cancers such as
mesothelioma and ovarian cancer. Phase
2 studies to begin shortly for
combination therapy using SS1P and
standard chemotherapy.
In addition to an active
Investigational New Drug (IND)
application, there are two associated
orphan drug designations with this
agent.
Inventors: Ira Pastan (NCI) et al.
Relevant Publications:
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
1. R Hassan et al. Phase I study of
SS1P, a recombinant anti-mesothelin
immunotoxin given as a bolus I.V.
infusion to patients with mesothelinexpressing mesothelioma, ovarian, and
pancreatic cancers. Clin Cancer Res.
2007 Sep 1;13 (17):5144–5149.
2. Y Zhang et al. Synergistic
antitumor activity of taxol and
immunotoxin SS1P in tumor-bearing
mice. Clin Cancer Res. 2006 Aug
1;12(15):4695–4701.
Patent Status: U.S. Patent No.
7,081,518 issued 25 Jul 2006, entitled
‘‘Anti-Mesothelin Antibodies Having
High Binding Affinity’’ (HHS Reference
No. E–139–1999/0–US–07)
Related Intellectual Property:
1. U.S. Patent No. 4,892,827 entitled
‘‘Recombinant Pseudomonas Exotoxin:
Construction of an Active Immunotoxin
with Low Side Effects’’ [HHS Ref. No.
E–385–1986/0];
2. U.S. Patent Nos. 6,051,405,
5,863,745, and 5,696,237 ‘‘Recombinant
Antibody-Toxin Fusion Protein’’ [HHS
Ref. No. E–135–1989/0];
3. U.S. Patents 5,747,654, 6,147,203,
and 6,558,672 entitled ‘‘Recombinant
Disulfide-Stabilized Polypeptide
Fragments Having Binding Specificity’’
[HHS Ref. No. E–163–1993/0];
4. U.S. Patent No. 6,153,430, and U.S.
Patent Application No. 09/684,599
‘‘Nucleic Acid Encoding Mesothelin, a
Differentiation Antigen Present on
Mesothelium, Mesotheliomas and
Ovarian Cancers’’ [HHS Ref. No. E–002–
1996/0];
5. U.S. Patent 6,083,502 entitled
‘‘Mesothelium Antigen and Methods
and Kits for Targeting It’’ [HHS Ref. No.
E–002–1996/1];
6. U.S. Patent Application 09/581,345:
‘‘Antibodies, Including Fv Molecules,
and Immunoconjugates Having High
Binding Affinity for Mesothelin and
Methods for Their Use’’ [HHS Ref. No.
E–021–1998/0];
7. PCT Application No. PCT/US01/
18503, ‘‘Pegylation of Linkers Improves
Antitumor Activity and Reduces
Toxicity of Immunoconjugates’’ [HHS
Ref. No. E–216–2000/2];
8. PCT Application No. PCT/US2006/
018502 and U.S. Patent Application No.
60/681,104, entitled ‘‘Anti-Mesothelin
Antibodies Useful For Immunological
Assays’’ [HHS Ref. No. E–015–2005/0–
US–01]; and
9. And any related foreign filed
national stage applications claiming
priority to such patent applications and
patents listed above.
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: David A.
Lambertson, Ph.D.; 301/435–4632;
lambertsond@mail.nih.gov.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
72743
cDNA Encoding a Gene BOG and Its
Protein Product
Description of Invention: Available for
licensing is BOG (B5t Over-Expressed
Gene) with the gene product pRb of the
well-known tumor suppressor gene RB,
retinoblastoma susceptibility gene. The
complex formed between Rb and BOG
typically does not contain E2F–1 in
vivo. This binding property suggests that
cells which are transformed/transfected
with cDNA or other functional
nucleotide sequences which encode the
BOG gene product will be useful as
tools for studying cell cycle control and
oncogenesis.
Studies using rat liver epithelial cell
(RLE) lines which are resistant to the
growth inhibitory effects of TGF-beta1
and primary liver tumors have been
shown to over-express BOG. Moreover,
when normal RLE continuously overexpress BOG the cells become
transformed and the transformed cells
are able to form hepatoblastoma-like
tumors when transplanted into nude
mice. Therefore, biologics derived from
BOG may be useful as diagnostics or
therapeutics.
Applications: Method to diagnose and
treat liver cancer; Method to study cell
cycle control and oncogenesis; Liver
cancer therapeutics.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market: Liver cancer is the third
leading cause of cancer death
worldwide, and the fifth most common
cancer in the world; Post-operative five
year survival rate of HCC patients is 30–
40%.
Inventors: Snorri S. Thorgeirsson et
al. (NCI).
Relevant Publication: JT Woitach et
al. A retinoblastoma-binding protein
that affects cell-cycle control and
confers transforming ability. Nat Genet.
1998 Aug;19(4):371–374.
Patent Status: U.S. Patent No.
6,727,079 issued 27 Apr 2004 (HHS
Reference No. E–009–1998/2–US–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong,
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute (NCI),
Center for Cancer Research, Laboratory
of Experimental Carcinogenesis, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
BOG (B5t Over-Expressed Gene) with
the gene product pRb. Please contact
John Hewes, Ph.D. at the NCI
Technology Transfer Center at
E:\FR\FM\21DEN1.SGM
21DEN1
72744
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
hewesj@mail.nih.gov or (301) 496–0477
for more information.
Dated: December 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–24784 Filed 12–20–07; 8:45 am]
BILLING CODE 4140–01–P
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Emergency Response
Grants Regulations—42 CFR part 51—
(OMB No. 0930–0229)—Extension
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
This rule implements section 501(m)
of the Public Health Service Act (42
U.S.C 290aa), which authorizes the
Secretary to make noncompetitive
grants, contracts or cooperative
agreements to public entities to enable
such entities to address emergency
substance abuse or mental health needs
in local communities. The rule
establishes criteria for determining that
a substance abuse or mental health
emergency exists, the minimum content
for an application, and reporting
requirements for recipients of such
funding. SAMHSA will use the
information in the applications to make
a determination that the requisite need
exists; that the mental health and/or
substance abuse needs are a direct result
of the precipitating event; that no other
local, state, tribal or Federal funding
sources available to address the need;
that there is an adequate plan of
services; that the applicant has
appropriate organizational capability;
and, that the budget provides sufficient
justification and is consistent with the
documentation of need and the plan of
Responses
per
respondent
Number of
respondents
42 CFR citation
services. Eligible applicants may apply
to the Secretary for either of two types
of substance abuse and mental health
emergency response grants: Immediate
awards and Intermediate awards. The
former are designed to be funded up to
$50,000, or such greater amount as
determined by the Secretary on a caseby-case basis, and are to be used over
the initial 90-day period commencing as
soon as possible after the precipitating
event; the latter awards require more
documentation, including a needs
assessment, other data and related
budgetary detail. The Intermediate
awards have no predefined budget limit.
Typically, Intermediate awards would
be used to meet systemic mental health
and/or substance abuse needs during
the recovery period following the
Immediate award period. Such awards
may be used for up to one year, with a
possible second year supplement based
on submission of additional required
information and data. This program is
an approved user of the PHS–5161
application form, approved by OMB
under control number 0920–0428. The
quarterly financial status reports in
51d.10(a)(2) and (b)(2) are as permitted
by 45 CFR 92.41(b); the final program
report, financial status report and final
voucher in 51d.10(a)(3) and in
51d.10(b)(3–4) are in accordance with
45 CFR 92.50(b). Information collection
requirements of 45 CFR part 92 are
approved by OMB under control
number 0990–0169. The following table
presents annual burden estimates for the
information collection requirements of
this regulation.
Hours per
response
Annual burden
hours
Immediate award application:
51d.4(a) and 51d.6(a)(2) ..........................................................................
51d.4(b) and 51d.6(a)(2) Immediate Awards ...........................................
51d.10(a)(1)—Immediate awards—mid-program report if applicable ......
Final report content for both types of awards:
51d.10(c) ...................................................................................................
3
3
3
1
1
1
3
10
2
*9
*30
*6
6
1
3
18
Total ...................................................................................................
6
........................
........................
18
mstockstill on PROD1PC66 with NOTICES
* This burden is carried under OMB No. 0920–0428.
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
Room 7–1044, One Choke Cherry Road,
Rockville, MD 20857 AND e-mail her a
copy at summer.king@samhsa.hhs.gov.
Written comments should be received
within 60 days of this notice.
Dated: December 13, 2007.
Elaine Parry,
Acting Director, Office of Program Services.
[FR Doc. E7–24824 Filed 12–20–07; 8:45 am]
DEPARTMENT OF HOMELAND
SECURITY
Bureau of Customs and Border
Protection
BILLING CODE 4162–20–P
Oral Declarations No Longer
Satisfactory as Evidence of Citizenship
and Identity
U.S. Customs and Border
Protection, Department of Homeland
Security.
AGENCIES:
VerDate Aug<31>2005
18:54 Dec 20, 2007
Jkt 214001
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 72, Number 245 (Friday, December 21, 2007)]
[Notices]
[Pages 72742-72744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-24784]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
[[Page 72743]]
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Clinically Proven Therapeutic Treatment and Diagnostic Tool for
Mesothelin Expressing Cancers: A Novel Recombinant Immunotoxin SS1P
(anti-mesothelin dsFv-PE38)
Description of Technology: Mesothelin is a cell surface
glycoprotein, whose expression is largely restricted to mesothelial
cells in normal tissues. Mesothelin has been shown to be highly
expressed in many cancers including malignant mesothelioma, ovarian
cancer, lung cancer, pancreatic carcinomas, gastric carcinomas, and
other cancers. Mesothelin has been shown to be a target for
immunotherapy and is also being used as a tumor marker.
The technology relates to the SS1P immunotoxin that can be used to
kill cells expressing mesothelin on their surface, such as
mesothelioma, ovarian cancer, lung cancer, pancreatic cancer and
stomach cancer. Additionally, it can be used for the detection of
mesothelin expressing cells present in a biological sample.
The SSIP protein is an immunotoxin generated by the fusion of an
anti-mesothelin antibody Fv fragment with a particularly high affinity
(SS1), and a ~38 kDa portion of Pseudomonas Exotoxin A (PE38).
Applications: SS1P can be used as a therapy for mesothelin
expressing cancers. The immunotoxin can be used as a standalone
treatment and in combination with standard chemotherapy.
Advantage: SS1P immunotoxin is available for use and has been
successfully tested clinically for the treatment of several mesothelin
expressing cancers, such as mesothelioma and ovarian cancer with low
side effects.
Development Status: Phase 1 studies have been completed for
mesothelin expressing cancers such as mesothelioma and ovarian cancer.
Phase 2 studies to begin shortly for combination therapy using SS1P and
standard chemotherapy.
In addition to an active Investigational New Drug (IND)
application, there are two associated orphan drug designations with
this agent.
Inventors: Ira Pastan (NCI) et al.
Relevant Publications:
1. R Hassan et al. Phase I study of SS1P, a recombinant anti-
mesothelin immunotoxin given as a bolus I.V. infusion to patients with
mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Clin Cancer Res. 2007 Sep 1;13 (17):5144-5149.
2. Y Zhang et al. Synergistic antitumor activity of taxol and
immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res. 2006 Aug
1;12(15):4695-4701.
Patent Status: U.S. Patent No. 7,081,518 issued 25 Jul 2006,
entitled ``Anti-Mesothelin Antibodies Having High Binding Affinity''
(HHS Reference No. E-139-1999/0-US-07)
Related Intellectual Property:
1. U.S. Patent No. 4,892,827 entitled ``Recombinant Pseudomonas
Exotoxin: Construction of an Active Immunotoxin with Low Side Effects''
[HHS Ref. No. E-385-1986/0];
2. U.S. Patent Nos. 6,051,405, 5,863,745, and 5,696,237
``Recombinant Antibody-Toxin Fusion Protein'' [HHS Ref. No. E-135-1989/
0];
3. U.S. Patents 5,747,654, 6,147,203, and 6,558,672 entitled
``Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding
Specificity'' [HHS Ref. No. E-163-1993/0];
4. U.S. Patent No. 6,153,430, and U.S. Patent Application No. 09/
684,599 ``Nucleic Acid Encoding Mesothelin, a Differentiation Antigen
Present on Mesothelium, Mesotheliomas and Ovarian Cancers'' [HHS Ref.
No. E-002-1996/0];
5. U.S. Patent 6,083,502 entitled ``Mesothelium Antigen and Methods
and Kits for Targeting It'' [HHS Ref. No. E-002-1996/1];
6. U.S. Patent Application 09/581,345: ``Antibodies, Including Fv
Molecules, and Immunoconjugates Having High Binding Affinity for
Mesothelin and Methods for Their Use'' [HHS Ref. No. E-021-1998/0];
7. PCT Application No. PCT/US01/18503, ``Pegylation of Linkers
Improves Antitumor Activity and Reduces Toxicity of Immunoconjugates''
[HHS Ref. No. E-216-2000/2];
8. PCT Application No. PCT/US2006/018502 and U.S. Patent
Application No. 60/681,104, entitled ``Anti-Mesothelin Antibodies
Useful For Immunological Assays'' [HHS Ref. No. E-015-2005/0-US-01];
and
9. And any related foreign filed national stage applications
claiming priority to such patent applications and patents listed above.
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: David A. Lambertson, Ph.D.; 301/435-4632;
lambertsond@mail.nih.gov.
cDNA Encoding a Gene BOG and Its Protein Product
Description of Invention: Available for licensing is BOG (B5t Over-
Expressed Gene) with the gene product pRb of the well-known tumor
suppressor gene RB, retinoblastoma susceptibility gene. The complex
formed between Rb and BOG typically does not contain E2F-1 in vivo.
This binding property suggests that cells which are transformed/
transfected with cDNA or other functional nucleotide sequences which
encode the BOG gene product will be useful as tools for studying cell
cycle control and oncogenesis.
Studies using rat liver epithelial cell (RLE) lines which are
resistant to the growth inhibitory effects of TGF-beta1 and primary
liver tumors have been shown to over-express BOG. Moreover, when normal
RLE continuously over-express BOG the cells become transformed and the
transformed cells are able to form hepatoblastoma-like tumors when
transplanted into nude mice. Therefore, biologics derived from BOG may
be useful as diagnostics or therapeutics.
Applications: Method to diagnose and treat liver cancer; Method to
study cell cycle control and oncogenesis; Liver cancer therapeutics.
Development Status: The technology is currently in the pre-clinical
stage of development.
Market: Liver cancer is the third leading cause of cancer death
worldwide, and the fifth most common cancer in the world; Post-
operative five year survival rate of HCC patients is 30-40%.
Inventors: Snorri S. Thorgeirsson et al. (NCI).
Relevant Publication: JT Woitach et al. A retinoblastoma-binding
protein that affects cell-cycle control and confers transforming
ability. Nat Genet. 1998 Aug;19(4):371-374.
Patent Status: U.S. Patent No. 6,727,079 issued 27 Apr 2004 (HHS
Reference No. E-009-1998/2-US-02).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong, 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
(NCI), Center for Cancer Research, Laboratory of Experimental
Carcinogenesis, is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize BOG (B5t Over-Expressed Gene) with the gene
product pRb. Please contact John Hewes, Ph.D. at the NCI Technology
Transfer Center at
[[Page 72744]]
hewesj@mail.nih.gov or (301) 496-0477 for more information.
Dated: December 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-24784 Filed 12-20-07; 8:45 am]
BILLING CODE 4140-01-P
